Amgen Inc. (AMGN)

224.89
2.27 1.00
NASDAQ
Prev Close 227.16
Open 226.02
Day Low/High 221.79 / 228.23
52 Wk Low/High 177.05 / 264.97
Volume 3.09M
Exchange NASDAQ
Shares Outstanding 585.69B
Market Cap 133.53B
P/E Ratio 18.61
Div & Yield N.A. (N.A)
5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

Charts Show Something Broke Friday

Charts Show Something Broke Friday

Often, pictures speak louder than words.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Stocks secure robust gains after the latest labor market snapshot breezes past expectations.

Housing, Biotech Offer Affordable Growth

Housing, Biotech Offer Affordable Growth

These sectors offer value as the S&P 500 trades at 19x earnings.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Can Amgen Break Out?

Can Amgen Break Out?

The company has pushed to the top of a large consolidation pattern.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Amgen estimates, target increased at BMO

Facebook Blows Away Estimates, Stock Soars to All-Time High

Facebook Blows Away Estimates, Stock Soars to All-Time High

Facebook (FB) smashed earnings expectations--again. Shares are hitting record highs in the pre-market.

Market Ends Weak as Rate Hike Put Off: See You in September?

Market Ends Weak as Rate Hike Put Off: See You in September?

Stocks remain very unconcerned about rates, despite the odds of a fall increase slightly rising.

I'm Bullish on Biotechs

The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

Amgen's Struggle Means It's Time to Play 'D'

Amgen's Struggle Means It's Time to Play 'D'

Traders and investors should either stand aside or start probing the short side.

Amgen Poised For Another Steep Drop

Amgen Poised For Another Steep Drop

Shares of Amgen could be facing a deep selloff.

3 Finds in Biotech's 'Pocket of Value'

3 Finds in Biotech's 'Pocket of Value'

Large biotech stocks are still at their cheapest valuations since 2011.

Is Amgen Firming Up?

Is Amgen Firming Up?

A fresh rally leg could be on the way if AMGN can remain above the $152 area in the near term. 

Remain Patient in This Sideways Market

Remain Patient in This Sideways Market

Keep cash on hand and be ready for oportunities as they arise.

Intermediate Trade: International Paper

Intermediate Trade: International Paper

I prefer a bullish synthetic call.

The Bearish Scenario in the S&P Is Still Intact

The Bearish Scenario in the S&P Is Still Intact

But there is no guarantee that it will fully play out.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

What's Next for Stocks and Bonds?

What's Next for Stocks and Bonds?

The S&P 500 is testing the neckline of a head-and-shoulders pattern.

Intermediate Trade: Amgen

Intermediate Trade: Amgen

The cream of the biotech crop seems to have found a floor after a rough set of earnings.

This Was One Dismal Earnings Season

This Was One Dismal Earnings Season

And it's hard to get excited about the second quarter, too.

Charts See Possible Value in Apple, Facebook

We also look at Amgen and the biotech index.